BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) | RFA NS 21 027

Opportunity Information: Apply for RFA NS 21 027

The BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed) funding opportunity (RFA-NS-21-027) is an NIH BRAIN Initiative cooperative agreement designed to push promising neuroscience tools from early proof-of-concept into more refined, reliable, and widely usable research technologies. It is a reissue of an earlier announcement (RFA-NS-18-019) and is grounded in the BRAIN Initiative priority of understanding how neural circuits operate dynamically in real time. The core idea is that transformative neurotechnology does not become broadly useful just because it works once in a specialized lab; it becomes transformative when it can be iteratively improved, validated in realistic experimental settings, and packaged in ways that everyday neuroscience researchers can adopt.

This FOA specifically targets technologies for recording and modulation of nervous system activity, with an emphasis on addressing major, practical bottlenecks that limit what scientists can measure or control in the central nervous system (CNS). Recording can include approaches that capture activity from cells and networks, while modulation covers stimulation/activation, inhibition, and other forms of manipulation. Importantly, the FOA is not limited to neurons alone; it also welcomes tools that can record from or modulate non-neuronal cell types, reflecting the growing recognition that glia and other cellular players contribute meaningfully to brain function. The goal is to enable a more complete and mechanistic understanding of signaling in the CNS, especially at the level of circuits and networks where behavior and cognition emerge.

A defining feature of this opportunity is its focus on optimization rather than invention from scratch. Applicants are expected to propose technologies or approaches that have already demonstrated transformative potential through initial proof-of-concept testing, and that are now ready for accelerated refinement. That refinement is expected to happen through iterative testing with end users, meaning the people who will realistically use the technology in neuroscience experiments. This emphasis on end-user feedback is meant to surface real-world issues early, such as usability, robustness, data quality, experimental compatibility, training burden, and reproducibility across labs. In practice, competitive proposals would typically include plans for systematic benchmarking, reliability testing, and user-centered redesign cycles that lead to measurable improvements.

The FOA also stresses that manufacturing and dissemination matter. Applicants are expected to consider scalable manufacturing techniques so that resulting tools can be produced sustainably and distributed broadly, rather than remaining custom-built prototypes. The intention is to support technologies that can be incorporated into routine neuroscience research, which often requires attention to standardization, documentation, workflow integration, maintenance, and cost. This can include design-for-manufacture considerations, quality control strategies, and plans that make the technology easier to adopt outside the developer's home institution.

In terms of experimental readiness, proposed technologies should be compatible with experiments in behaving animals and validated under in vivo experimental conditions. That requirement signals that the NIH is looking for tools that can perform under the constraints of realistic neuroscience studies, such as motion, biological variability, surgical limitations, chronic implantation demands, and long-term stability. The FOA explicitly aims to reduce major barriers that slow or prevent neurobiological experiments and, by doing so, accelerate new discoveries about the CNS. In other words, the success metric is not only technical novelty, but also whether the optimized tool materially expands what experiments can be done and improves the reliability and interpretability of results.

The opportunity is intentionally broad about what kinds of signals and modalities are acceptable. While electrical activity is a traditional focus, the FOA welcomes recording and manipulation methods that rely on optical, electrical, magnetic, acoustic, genetic, or other mechanisms. This framing supports a wide range of approaches, such as advanced optical reporters and imaging, novel electrode or probe systems, magnetically or acoustically mediated neuromodulation concepts, and genetic strategies that enable cell-type-specific control or readout. Applications that integrate multiple approaches are encouraged, reflecting a recognition that major advances often come from combining complementary methods (for example, pairing high-resolution recording with targeted modulation, or integrating hardware with computational models that improve signal extraction and interpretation).

Because these projects often sit at the intersection of many technical domains, the FOA notes that applications are expected, when appropriate, to integrate expertise across biological, chemical, and physical sciences, engineering, computational modeling, and statistical analysis. This is both a practical expectation and a signal about review priorities: technologies that generate complex data or require sophisticated validation typically need strong analytical frameworks and rigorous experimental design to demonstrate performance improvements and generalizability.

Administratively, the mechanism is a U01 cooperative agreement, which generally means NIH staff will have substantial scientific and programmatic involvement during the project compared to a standard research grant. The FOA falls under NIH (AgencyName: National Institutes of Health) and is categorized as a discretionary opportunity with an activity category that spans education, health, and social services. Clinical trials are not allowed under this announcement, so proposals should be focused on preclinical technology development and validation rather than interventional studies in human participants.

Eligibility is broad and includes a wide range of organization types: state, county, and local governments; special districts; independent school districts; public and state-controlled and private institutions of higher education; federally recognized Native American tribal governments and other tribal organizations; public housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; and other entities. The announcement also highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, AANAPISI institutions, Hispanic-serving institutions, HBCUs, tribally controlled colleges and universities, faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-U.S. (foreign) organizations. The original closing date listed for this opportunity was 2023-02-08, and the posted record shows the creation date as 2021-06-08. Several CFDA numbers are associated with the opportunity (93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866), reflecting its alignment with multiple NIH programs and institutes that support neuroscience and related research infrastructure.

Overall, this FOA is aimed at taking already-promising neurotechnology and making it genuinely field-ready: more robust, more user-friendly, validated in vivo in behaving animals, scalable to manufacture, and easier to disseminate so it can meaningfully broaden access to high-impact recording and modulation capabilities across the neuroscience community.

• The National Institutes of Health in the education, health, income security and social services sector is offering a public funding opportunity titled "BRAIN Initiative: Optimization of Transformative Technologies for Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.173, 93.213, 93.242, 93.273, 93.279, 93.286, 93.853, 93.865, 93.866.
• This funding opportunity was created on 2021-06-08.
• Applicants must submit their applications by 2023-02-08. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA NS 21 027

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: